Abstract
e21070Background: High-dose interferon alfa-2b(IFN-α-2b) improves the survival of high-risk melanoma patients, especially acral melanoma patient. However, there is a significant number of patients fails to benefit from treatment because of the toxicities. In this study, we aimed to identify baseline peripheral blood biomarkers to predict the outcome of acral melanoma patients with adjuvant high-dose interferon treatment. Methods: Pretreatment full blood counts, CD4+CD25+ regulatory T cells (CD4+Tregs),CD8+CD28-regulatory T cells(CD8+Tregs), CD8+CD28+cytotoxic T lymphocyte(CTL),serum lactate dehydrogenase (LDH), and clinical date were assessed in 113acral melanoma patients. 76 patients treated with 4-week IFN-α-2b (15*106 U/m2d1–5/w*4w) and 37 patients treated with1-year IFN-α-2b (15*106 U/m2 d1–5/w*4w + 9*106 U tiw*48w). Relapse free survival (RFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and multivariate Cox regression analysis were applied, adjusting for other prognostic fa...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
